A recent JAMA Network Open study verified and expanded our knowledge of the benefits of ADHD drugs like amphetamines and methylphenidate. The study of approximately 221,700 ADHD patients found that these medicines reduced psychiatric hospitalizations and improved mental health.
Amphetamine reduced hospitalization by 25% compared to other stimulants, and lisdexamphetamine and other medicines had similar effects. These drugs also reduced suicide attempts, proving their mental health benefits.
Atomoxetine, a non-stimulant used when stimulants are not appropriate, reduces job impairment in younger ADHD patients. This displays the variety of ADHD management strategies that increase functionality and quality of life.
Healthcare providers and ADHD sufferers benefit from the research. They note that ADHD drugs may reduce psychiatric hospitalizations, suicidal behavior, and employment impairment. We can use this knowledge to improve ADHD management and outcomes.
